VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.21
-0.27 (-1.46%)
At close: 4:00PM EDT

18.21 0.00 (0.00%)
After hours: 4:41PM EDT

Stock chart is not supported by your current browser
Previous Close18.48
Open18.45
Bid18.00 x 800
Ask18.54 x 1000
Day's Range17.89 - 18.64
52 Week Range11.54 - 31.91
Volume225,914
Avg. Volume426,648
Market Cap590.66M
Beta2.93
PE Ratio (TTM)N/A
EPS (TTM)-2.71
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.27
Trade prices are not sourced from all markets
  • Analysts Remain Bullish on BioMarin Pharmaceutical
    Market Realist7 days ago

    Analysts Remain Bullish on BioMarin Pharmaceutical

    Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.

  • Analyzing Audentes Therapeutics’ Valuation Metrics
    Market Realist8 days ago

    Analyzing Audentes Therapeutics’ Valuation Metrics

    Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with a net loss of $22.74 million in the second quarter of 2017. That translates to a net loss per share of $0.85 in the second quarter of 2018. Its net loss per share was $0.87 in the second quarter of 2017.

  • GlobeNewswire24 days ago

    Voyager Therapeutics to Present at Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations ...

  • Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
    Zackslast month

    Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

    Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -26.98% and -14.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Voyager Therapeutics: 2Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 80 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights

    Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’ s disease. Pipeline programs progressing with updated preclinical data from ALS ...

  • ACCESSWIRElast month

    Voyager Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Voyager Therapeutics, Inc. (NASDAQ: VYGR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • GlobeNewswire2 months ago

    Voyager Therapeutics to Present at Investor Conferences in August

    CAMBRIDGE, Mass., Aug. 02, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations ...

  • GlobeNewswire2 months ago

    Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call

    CAMBRIDGE, Mass., July 31, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its second quarter ...

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

    For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.

  • Benzinga2 months ago

    Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

    The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...

  • GlobeNewswire2 months ago

    Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA).  Based on the written response from the FDA, Voyager continues to plan to submit for review a biologics license application (BLA) for VY-AADC based on the nonclinical and clinical safety and efficacy data from the pivotal program, including plans to submit a BLA based on data from the randomized, placebo-controlled Phase 2 trial alone, or if needed, from the randomized, placebo-controlled Phase 3 trial. In addition, Voyager today announced positive interim results from a Phase 1 posterior trajectory trial that achieved enhanced coverage of the putamen, reduced surgical times, and improvements in patients’ motor function at six months that were consistent with improvements achieved from patients in Cohorts 2 and 3 at the same time point in Voyager’s Phase 1b trial with VY-AADC.

  • ACCESSWIRE3 months ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • GlobeNewswire3 months ago

    Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced the appointment of G. Andre Turenne as president and chief executive officer of Voyager effective July 16, 2018, at which time he will also become a member of the Voyager Board of Directors. Mr. Turenne joins Voyager with extensive strategic business development and commercial leadership experience, including nearly 12 years at Genzyme and Sanofi where he most recently served as Sanofi’s senior vice president, global head, business development and licensing responsible for partnering activities across all of Sanofi’s business units.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Casi Pharmaceuticals Inc (NASDAQ: CASI ) stock was ...

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • Benzinga4 months ago

    The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

    The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space. Here's a compilation of key biotech ...

  • Associated Press4 months ago

    Voyager Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...